Merck KGaA

MRK

DE0006599905

Pharmaceuticals

Real-time Estimate Tradegate Other stock markets 08:48:32 17/07/2024 pm IST			5-day change	1st Jan Change
154.1 ^EUR	+0.05%		+3.35%	+6.97%

10/07	Merck KGaA: share price down, analyst lowers target	CF
10/07	MERCK KGAA : UBS lowers price target	CF

MERCK KGAA : JP Morgan remains Neutral

January 06, 2020 at 07:11 pm IST

Analyst Richard Vosser from JP Morgan research gives the stock a Neutral rating. The target price has been lifted and is now set at EUR 110 compared to EUR 104 before.

Latest news about Merck KGaA

Merck KGaA: share price down, analyst lowers target	10/07	CF
MERCK KGAA : UBS lowers price target	10/07	CF
UBS lowers target for Merck KGaA to 178 euros - 'Buy'	10/07	DP
MERCK KGAA : UBS keeps its Buy rating	10/07	ZD
Dawn Health and Merck Collaborate to Support Growth Disorders Care	01/07	CI
Chemicals collective agreement: Bonus days for union members	27/06	DP
Chemicals collective bargaining agreement: extra day for trade unionists	27/06	DP
Chemical industry wage partners seek solution before the end of the peace period	26/06	DP
German Stocks Fall Tuesday	25/06	DJ
Market Update-Europe closes lower in a session marked by a wait-and-see attitude	25/06	RE
Global markets live: UBS, Boeing, AT&T, Rivian, Nvidia, Tesla...	25/06
MERCK KGAA : Barclays cuts its target price	25/06	CF
MERCK KGAA : Gets a Neutral rating from Bernstein	25/06	ZD
MERCK KGAA : failure in head and neck cancer trial	25/06	CF
UBS reiterates Merck KGaA at 'Buy' - Target 186 euros	25/06	DP
Next pharmaceutical study flop for Merck KGaA - share price collapses	25/06	DP
European shares fall as Airbus hammers aerospace shares, tech slips	25/06	RE
Merck KGaA shocks investors with end to cancer drug program	25/06	DP
Merck KGaA Shares Drop After Canceled Late-Stage Cancer Drug Study	25/06	DJ
FTSE 100 edges up but mood tetchy amid US tech woe	25/06	AN
MERCK KGAA : UBS maintains a Buy rating	25/06	ZD
Shares Frankfurt opening: Airbus weighs on Dax with profit warning	25/06	DP
Merck KGaA shares plunge after cancer drug hopeful fails	25/06	RE
European shares open lower on Airbus, tech drag	25/06	RE
Barclays lowers target for Merck KGaA to 195 euros - 'Overweight'	25/06	DP

Merck KGaA is one of the world's leading pharmaceutical and chemical groups. Net sales break down by family of products as follows: - solutions and products for scientific and biotechnological research (44.2%); - pharmaceutical products (38.4%): prescription drugs for the treatment of diabetes, cancer, multiple sclerosis, infertility, cardiovascular disease, central nervous system disorders, inflammatory disorders, etc.; - performance materials for the electronics industry (17.4%): semiconductor materials, liquid crystals, pigments and additives, carbon-based organic materials, etc. Net sales are distributed geographically as follows: Germany (4.8%), Europe (24%), China (12.9%), Asia/Pacific (20.1%), the United States (26.8%), North America (1.6%), Latin America (6.3%), Middle East and Africa (3.5%).

Sector

Pharmaceuticals

Calendar

01/08/2024 - Q2 2024 Earnings Call

Related indices

STOXX EUROPE 600 (EUR) , DAX

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

MERCK : A lower starting point for future growth

May 27, 2024 at 01:06 pm IST

Merck KGaA : A European big pharma with positive momentum

January 20, 2023 at 04:21 pm IST

More Strategies

Ratings for Merck KGaA

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

154 EUR

Average target price

183 EUR

Spread / Average Target

+18.83%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
MERCK KGAA	+6.97%	7.29TCr
KYOWA KIRIN CO. LTD.	+34.09%	1.03TCr
YUHAN CORPORATION	+40.84%	522.86Cr
SK BIOPHARMACEUTICALS CO., LTD.	-18.53%	462.47Cr
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+12.65%	352.27Cr
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+26.25%	230.61Cr
BETTA PHARMACEUTICALS CO., LTD.	-39.96%	178.31Cr
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-44.54%	168.96Cr
VELOXIS PHARMACEUTICALS A/S	-0.50%	164.41Cr
SUPERNUS PHARMACEUTICALS, INC.	+0.24%	159.1Cr

Specialty & Advanced Pharmaceuticals

Merck KGaA

Equities

MRK

DE0006599905

Pharmaceuticals

MERCK KGAA : JP Morgan remains Neutral

Latest news about Merck KGaA

Chart Merck KGaA

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Merck KGaA

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Specialty & Advanced Pharmaceuticals